Small molecule · Inhibitor of FGFR2 and FGFR3 · developed by Cogent Biosciences
CGT4859 is an orally bioavailable reversible inhibitor of fibroblast growth factor receptors 2 and 3 (FGFR2/3). It selectively binds to and inhibits FGFR2/3, including molecular brake and gatekeeper resistance mutations, blocking FGFR-mediated signaling and tumor cell proliferation. It is being studied in intrahepatic cholangiocarcinoma and other solid tumors with FGFR2/3 alterations.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06777316 | Phase 1/2 | Intrahepatic Cholangiocarcinoma (Icc) | Active not recruiting | COGT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsCholangiocarcinomaFGFR2 Gene AmplificationFGFR2 Gene Fusion/RearrangementFGFR2 Gene Short VariantsFGFR2 Genetic AlterationsFGFR3 Gene AmplificationFGFR3 Gene Fusion/RearrangementFGFR3 Gene Short VariantsFGFR3 Genetic AlterationsIntrahepatic Cholangiocarcinoma (Icc)Other Solid Tumors, Adult
Updated Oct 3, 2026. Something wrong or missing? Report it on the COGT page.
See COGT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
COGT catalysts and pipeline →